Archives

Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease

July 25, 2025 NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)– Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for […]

The Label of ‘Warrior’: Do We Need It to Feel Strong?

“You’re such a warrior.” People say it with admiration, as if it’s a badge I should wear proudly. But what if I don’t always want to be a warrior? What […]

Huntington Academy, a new e-learning platform dedicated to HD, is now available

The European Huntington Association, with the support of a grant from the European Union, and in collaboration with the Ligue Huntington Francophone Belge, the Bulgarian Huntington Association and the ACHE […]

Practicing Mindfulness with HD: Learning to Be Here Now

Living with Huntington’s Disease has taught me many things, but one of the most important lessons has been this: presence is a practice. Before my diagnosis, I didn’t give much […]

PTC518 PIVOT-HD Study Achieves Primary Endpoint

May 5, 2025 PDF Version – Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 – – Favorable dose-dependent trends across clinical scales in Stage 2 […]

May Awareness Month 2025 – Shining a light on HD: One Action a Day

Every May, communities around the world come together to shine a light on Huntington’s Disease (HD). From families and caregivers to clinicians, researchers, and advocates, we are united by one […]

5 Self-Care Tips That Help Me Thrive with Huntington’s Disease

May is Huntington’s Disease Awareness Month a time to uplift the voices of those impacted, challenge stigma, and spotlight the strength that lives within our community. For me, this month […]

UniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application […]

Update on the Phase II GENERATION HD2 study

Roche has announced the continuation of the GENERATION HD2 Phase II clinical trial evaluating tominersen in individuals with early signs of Huntington’s disease. Following an interim analysis by an independent committee, no […]

EHA Conference 2025

We are excited to announce that the European Huntington Association will be organising its 5th Biannual Conference in Bucharest, Romania, from September 25th-28th, 2025. “Shaping our Future Together, We are the Change!” encapsulates the spirit […]